Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RO2L
|
|||
| Drug Name |
CAR-T cells targeting PSMA
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Cervical cancer [ICD-11: 2C77.0; ICD-9: 180] | Phase 1/2 | [1] | |
| Company |
Shenzhen Geno-Immune Medical Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glutamate carboxypeptidase II (GCPII) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
| Metabolic pathways | ||||
| Vitamin digestion and absorption | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| Reactome | Amino acid synthesis and interconversion (transamination) | |||
| WikiPathways | One Carbon Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.